Abstract
Both elevated levels of uric acid and non-alcoholic fatty liver disease (NAFLD) have been associated with increased vascular risk. Furthermore, certain drugs (e.g. lipid and blood pressure lowering) that decrease)cardiovascular risk and improve/preserve renal function were shown to influence serum uric acid (SUA) levels and/or NAFLD. A link between hyperuricaemia and NAFLD has also been suggested. This review considers the associations between hyperuricaemia, NAFLD and vascular risk. We also discuss the effects of different drug treatments on SUA and NAFLD. As NAFLD is a very common condition, future work in this field is needed with regard to a more practical definitive diagnosis, evidence- based treatments and a better understanding of the possible links between NAFLD, elevated SUA levels, cardiovascular disease and chronic kidney disease. Whether treating hyperuricaemia and NAFLD will translate into a reduced risk of vascular events requires further investigation.
Keywords: Antihypertensive treatment, lipid-lowering drugs, non-alcoholic fatty liver disease, uric acid, vascular risk, weightreducing agents, hyperuricaemia, metabolic syndrome, hypertension, obesity
Current Vascular Pharmacology
Title: Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?
Volume: 9 Issue: 6
Author(s): Niki Katsiki, Vasilios G. Athyros, Asterios Karagiannis and Dimitri P. Mikhailidis
Affiliation:
Keywords: Antihypertensive treatment, lipid-lowering drugs, non-alcoholic fatty liver disease, uric acid, vascular risk, weightreducing agents, hyperuricaemia, metabolic syndrome, hypertension, obesity
Abstract: Both elevated levels of uric acid and non-alcoholic fatty liver disease (NAFLD) have been associated with increased vascular risk. Furthermore, certain drugs (e.g. lipid and blood pressure lowering) that decrease)cardiovascular risk and improve/preserve renal function were shown to influence serum uric acid (SUA) levels and/or NAFLD. A link between hyperuricaemia and NAFLD has also been suggested. This review considers the associations between hyperuricaemia, NAFLD and vascular risk. We also discuss the effects of different drug treatments on SUA and NAFLD. As NAFLD is a very common condition, future work in this field is needed with regard to a more practical definitive diagnosis, evidence- based treatments and a better understanding of the possible links between NAFLD, elevated SUA levels, cardiovascular disease and chronic kidney disease. Whether treating hyperuricaemia and NAFLD will translate into a reduced risk of vascular events requires further investigation.
Export Options
About this article
Cite this article as:
Katsiki Niki, G. Athyros Vasilios, Karagiannis Asterios and P. Mikhailidis Dimitri, Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?, Current Vascular Pharmacology 2011; 9 (6) . https://dx.doi.org/10.2174/157016111797484152
DOI https://dx.doi.org/10.2174/157016111797484152 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipoprotein(a) is a Therapeutic Target for Cardiovascular Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Molecular Targets of Diabetic Vascular Complications and Potential New Drugs
Current Drug Targets Effect of Cardiovascular Injury on Catabolism of Adenosine and Adenosine 5-‘Triphosphate in Systemic Blood in a Freely Moving Rat Model In Vivo
Drug Metabolism Letters Impact of Genetic Polymorphisms and Drug – Drug Interactions on Clopidogrel and Prasugrel Response Variability
Current Drug Metabolism Chest Pain in Children
Current Pediatric Reviews Atherosclerotic Process in Seroreverter Children and Adolescents Exposed to Fetal Antiretroviral Therapy
Current HIV Research Serum Specific Vasopressin-Degrading Activity is Related to Blood Total Cholesterol Levels in Men but not in Women
Medicinal Chemistry Medical Applications of Hyperthermia Based on Magnetic Nanoparticles
Recent Patents on Biomedical Engineering (Discontinued) Biomarkers in Cardiomyopathies and Prediction of Sudden Cardiac Death
Current Pharmaceutical Biotechnology Quercetin in Attenuation of Ischemic/Reperfusion Injury: A Review
Current Molecular Pharmacology Mechanisms of Cardiovascular Changes in an Experimental Model of Syndrome X and Pharmacological Intervention on the Renin-Angiotensin- System
Current Vascular Pharmacology Platelets in Alzheimer’s Disease-Associated Cellular Senescence and Inflammation
Current Pharmaceutical Design Geriatric Evaluation of Oncological Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Similar Mechanisms Regulated by γ-Secretase are Involved in Both Directions of the Bi-Directional Notch-Delta Signaling Pathway as well as Play a Potential Role in Signaling Events Involving Type 1 Transmembrane Proteins
Current Stem Cell Research & Therapy TNF as a Target of Inflammation in Rheumatoid Arthritis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Pathophysiology of Uric Acid in Relation to Cardiovascular Disease
Current Cardiology Reviews miR-666-3p Mediates the Protective Effects of Mesenchymal Stem Cell-derived Exosomes Against Oxygen-glucose Deprivation and Reoxygenation- induced Cell Injury in Brain Microvascular Endothelial Cells via Mitogen-activated Protein Kinase Pathway
Current Neurovascular Research Cellular Signaling Crosstalk Between Multiple Receptors for Investigation of Pathophysiology in Multifactorial Diseases - What is Clinically-Relevant Crosstalk?
Current Medicinal Chemistry Pre-CKD- Do we Need Another Hero?
Current Vascular Pharmacology Vaccine Adjuvants: Key Tools for Innovative Vaccine Design
Current Topics in Medicinal Chemistry